New cocktail shows promise for tough head and neck cancers

NCT ID NCT02270814

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Jun 10, 2026 · Updated 21 times

Summary

This study tests a combination of three drugs (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants must have cancer that has spread or come back and cannot be removed by surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Sanford Cancer Center Oncology Clinic and Pharmacy

Sioux Falls, South Dakota, 57104, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

CANCER OF THE HEAD AND NECK HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA